Aditxt Announces First AditxtEngage™ Event, Continuing Series of Investor Opportunities to Engage with Company
October 02, 2020 16:05 ET
|
Aditx Therapeutics, Inc.
First AditxtEngage™Event with Amro Albanna, CEO, to be held on Tuesday, October 6that 4:30pm ET Mountain View, CA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc....
Former Chief Medical Officer and Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security, Dr. Jeffrey Runge, Appointed to Aditxt Board of Directors
October 01, 2020 08:00 ET
|
Aditx Therapeutics, Inc.
Dr. Runge brings 35 years’ experience as an Emergency Medicine Physician, Federal Government Executive and Public Policy Strategist Mountain View, CA, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via...
Aditx Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 16:30 ET
|
Aditx Therapeutics, Inc.
Virtual Presentation on Wednesday, September 16th at 3:00 PM EDT Loma Linda, CA, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the "Company")...
Aditx Therapeutics Announces Closing of Upsized $9.6 Million Follow-On Public Offering
September 10, 2020 09:43 ET
|
Aditx Therapeutics, Inc.
LOMA LINDA, CA, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies...
Physician and Media Personality Dr. Drew Pinsky, Dr. Drew, Joins Aditx Therapeutics as Senior Advisor to AditxtScore™ for Scoring the Immune System
September 10, 2020 08:51 ET
|
Aditx Therapeutics, Inc.
Will Serve as Advisor and Brand Ambassador to Overall Platform and Individual Applications Loma Linda, CA, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt)...
Aditxt Signs Collaboration Agreement with Salveo Diagnostics to Commercialize AditxtScore™ Platform Starting in Q4, 2020
September 03, 2020 09:00 ET
|
Aditx Therapeutics, Inc.
LOMA LINDA, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies focused on...
Aditx Therapeutics Announces Pricing of $9.6 Million Follow-On Public Offering
September 02, 2020 08:30 ET
|
Aditx Therapeutics, Inc.
LOMA LINDA, CA, Sept. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies...
Head of R&D for the New Analyte Ventures at Abbott Diabetes Care, Namvar Kiaie Joins Aditx Therapeutics’ Board of Directors
August 25, 2020 08:00 ET
|
Aditx Therapeutics, Inc.
Mr. Kiaie has Extensive Experience in Medical Device Product Development Loma Linda, CA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”)...
Aditxt Submits Emergency Use Authorization (EUA) Application for AditxtScore™ for COVID-19
August 24, 2020 08:30 ET
|
Aditx Therapeutics, Inc.
If Granted, EUA would Enable the Commercial Launch of AditxtScore for COVID-19 LOMA LINDA, CA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Aditx Therapeutics, Inc. (Aditxt) (the...
Former President of the Global Business Unit at Schering AG, Dr. Joachim-Friedrich Kapp, MD, PhD, to Lead Aditx Therapeutics Clinical Development, Autoimmunity
August 14, 2020 08:00 ET
|
Aditx Therapeutics, Inc.
30 Year Industry Veteran with FDA and EMA Experience will Assume Newly Created Executive Role Loma Linda, CA, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc....